Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,25047407,peak plasma concentration (C max,"Systemic exposure to ziprasidone was similar following administration alone or after pretreatment with armodafinil, as assessed by mean peak plasma concentration (C max, 52.1 vs 50.4 ng/mL) and area under the plasma concentration-time curve from time 0 to infinity (AUC0-∞, 544.6 vs 469.1 ng·h/mL).",Evaluation of the potential for a pharmacokinetic drug-drug interaction between armodafinil and ziprasidone in healthy adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25047407/),[ng] / [ml],52.1,11110,DB00745,Modafinil
,25047407,peak plasma concentration (C max,"Systemic exposure to ziprasidone was similar following administration alone or after pretreatment with armodafinil, as assessed by mean peak plasma concentration (C max, 52.1 vs 50.4 ng/mL) and area under the plasma concentration-time curve from time 0 to infinity (AUC0-∞, 544.6 vs 469.1 ng·h/mL).",Evaluation of the potential for a pharmacokinetic drug-drug interaction between armodafinil and ziprasidone in healthy adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25047407/),[ng] / [ml],50.4,11111,DB00745,Modafinil
,25047407,area under the plasma concentration-time curve from time 0 to infinity (AUC0-∞,"Systemic exposure to ziprasidone was similar following administration alone or after pretreatment with armodafinil, as assessed by mean peak plasma concentration (C max, 52.1 vs 50.4 ng/mL) and area under the plasma concentration-time curve from time 0 to infinity (AUC0-∞, 544.6 vs 469.1 ng·h/mL).",Evaluation of the potential for a pharmacokinetic drug-drug interaction between armodafinil and ziprasidone in healthy adults. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25047407/),[h·ng] / [ml],544.6,11112,DB00745,Modafinil
,25047407,area under the plasma concentration-time curve from time 0 to infinity (AUC0-∞,"Systemic exposure to ziprasidone was similar following administration alone or after pretreatment with armodafinil, as assessed by mean peak plasma concentration (C max, 52.1 vs 50.4 ng/mL) and area under the plasma concentration-time curve from time 0 to infinity (AUC0-∞, 544.6 vs 469.1 ng·h/mL).",Evaluation of the potential for a pharmacokinetic drug-drug interaction between armodafinil and ziprasidone in healthy adults. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25047407/),[h·ng] / [ml],469.1,11113,DB00745,Modafinil
,21118743,half-life,The R-isomer of racemic modafinil has a half-life of approximately15 hours; the S-isomer has a half-life of 4 to 5 hours.,"Pharmacokinetics of armodafinil and modafinil after single and multiple doses in patients with excessive sleepiness associated with treated obstructive sleep apnea: a randomized, open-label, crossover study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21118743/),h,15,25364,DB00745,Modafinil
,21118743,half-life,The R-isomer of racemic modafinil has a half-life of approximately15 hours; the S-isomer has a half-life of 4 to 5 hours.,"Pharmacokinetics of armodafinil and modafinil after single and multiple doses in patients with excessive sleepiness associated with treated obstructive sleep apnea: a randomized, open-label, crossover study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21118743/),h,4 to 5,25365,DB00745,Modafinil
,21118743,terminal half-lives,"Plasma drug concentration-versus-time curves suggested comparable terminal half-lives (mean [SD] values were 16.5 [4.44] and 14.4 [3.22] hours for armodafinil and modafinil, respectively) but higher systemic exposure with armodafinil than modafinil (mean [SD] AUC(0-∞) values were 108.8 [31.66] and 66.4 [20.06] microg · h/mL for armodafinil and modafinil, respectively), as indicated by the high geometric mean ratios for the AUC (the AUC(0-∞)) ratio after a single dose was 1.64 [95% CI, 1.60-1.68; P < 0.001], and the AUC(0-τ) ratio after multiple doses was 1.69 [95% CI, 1.65-1.72; P < 0.001]) and, to a lesser extent, the ratio of the maximum plasma drug concentration after multiple doses (C(max) ratio = 1.37 [95% CI, 1.33-1.41; P < 0.001]).","Pharmacokinetics of armodafinil and modafinil after single and multiple doses in patients with excessive sleepiness associated with treated obstructive sleep apnea: a randomized, open-label, crossover study. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21118743/),h,16.5,25366,DB00745,Modafinil
,21118743,terminal half-lives,"Plasma drug concentration-versus-time curves suggested comparable terminal half-lives (mean [SD] values were 16.5 [4.44] and 14.4 [3.22] hours for armodafinil and modafinil, respectively) but higher systemic exposure with armodafinil than modafinil (mean [SD] AUC(0-∞) values were 108.8 [31.66] and 66.4 [20.06] microg · h/mL for armodafinil and modafinil, respectively), as indicated by the high geometric mean ratios for the AUC (the AUC(0-∞)) ratio after a single dose was 1.64 [95% CI, 1.60-1.68; P < 0.001], and the AUC(0-τ) ratio after multiple doses was 1.69 [95% CI, 1.65-1.72; P < 0.001]) and, to a lesser extent, the ratio of the maximum plasma drug concentration after multiple doses (C(max) ratio = 1.37 [95% CI, 1.33-1.41; P < 0.001]).","Pharmacokinetics of armodafinil and modafinil after single and multiple doses in patients with excessive sleepiness associated with treated obstructive sleep apnea: a randomized, open-label, crossover study. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21118743/),h,14.4,25367,DB00745,Modafinil
,21118743,AUC(0-∞),"Plasma drug concentration-versus-time curves suggested comparable terminal half-lives (mean [SD] values were 16.5 [4.44] and 14.4 [3.22] hours for armodafinil and modafinil, respectively) but higher systemic exposure with armodafinil than modafinil (mean [SD] AUC(0-∞) values were 108.8 [31.66] and 66.4 [20.06] microg · h/mL for armodafinil and modafinil, respectively), as indicated by the high geometric mean ratios for the AUC (the AUC(0-∞)) ratio after a single dose was 1.64 [95% CI, 1.60-1.68; P < 0.001], and the AUC(0-τ) ratio after multiple doses was 1.69 [95% CI, 1.65-1.72; P < 0.001]) and, to a lesser extent, the ratio of the maximum plasma drug concentration after multiple doses (C(max) ratio = 1.37 [95% CI, 1.33-1.41; P < 0.001]).","Pharmacokinetics of armodafinil and modafinil after single and multiple doses in patients with excessive sleepiness associated with treated obstructive sleep apnea: a randomized, open-label, crossover study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21118743/),[h·μg] / [ml],108.8,25368,DB00745,Modafinil
,21118743,AUC(0-∞),"Plasma drug concentration-versus-time curves suggested comparable terminal half-lives (mean [SD] values were 16.5 [4.44] and 14.4 [3.22] hours for armodafinil and modafinil, respectively) but higher systemic exposure with armodafinil than modafinil (mean [SD] AUC(0-∞) values were 108.8 [31.66] and 66.4 [20.06] microg · h/mL for armodafinil and modafinil, respectively), as indicated by the high geometric mean ratios for the AUC (the AUC(0-∞)) ratio after a single dose was 1.64 [95% CI, 1.60-1.68; P < 0.001], and the AUC(0-τ) ratio after multiple doses was 1.69 [95% CI, 1.65-1.72; P < 0.001]) and, to a lesser extent, the ratio of the maximum plasma drug concentration after multiple doses (C(max) ratio = 1.37 [95% CI, 1.33-1.41; P < 0.001]).","Pharmacokinetics of armodafinil and modafinil after single and multiple doses in patients with excessive sleepiness associated with treated obstructive sleep apnea: a randomized, open-label, crossover study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21118743/),[h·μg] / [ml],66.4,25369,DB00745,Modafinil
,15740906,Recoveries,"Recoveries from urine and plasma were 80.0 and 98.9%, respectively and the limit of quantitation was 0.1 microg/mL at 233 nm.",Determination of modafinil in plasma and urine by reversed phase high-performance liquid-chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15740906/),%,80.0,27113,DB00745,Modafinil
,15740906,Recoveries,"Recoveries from urine and plasma were 80.0 and 98.9%, respectively and the limit of quantitation was 0.1 microg/mL at 233 nm.",Determination of modafinil in plasma and urine by reversed phase high-performance liquid-chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15740906/),%,98.9,27114,DB00745,Modafinil
,15993026,times,"The times for the unchanged modafinil to reach peak concentration in the urine of the three volunteers were at 2 h (6.14 microg/mL), 4 h (9.93 microg/mL) and 8 h (3.58 microg/mL), respectively.",Detection of modafinil in human urine by gas chromatography-mass spectrometry. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15993026/),h,2,38524,DB00745,Modafinil
,15993026,times,"The times for the unchanged modafinil to reach peak concentration in the urine of the three volunteers were at 2 h (6.14 microg/mL), 4 h (9.93 microg/mL) and 8 h (3.58 microg/mL), respectively.",Detection of modafinil in human urine by gas chromatography-mass spectrometry. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15993026/),[μg] / [ml],6.14,38525,DB00745,Modafinil
,15993026,times,"The times for the unchanged modafinil to reach peak concentration in the urine of the three volunteers were at 2 h (6.14 microg/mL), 4 h (9.93 microg/mL) and 8 h (3.58 microg/mL), respectively.",Detection of modafinil in human urine by gas chromatography-mass spectrometry. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15993026/),h,4,38526,DB00745,Modafinil
,15993026,times,"The times for the unchanged modafinil to reach peak concentration in the urine of the three volunteers were at 2 h (6.14 microg/mL), 4 h (9.93 microg/mL) and 8 h (3.58 microg/mL), respectively.",Detection of modafinil in human urine by gas chromatography-mass spectrometry. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15993026/),[μg] / [ml],9.93,38527,DB00745,Modafinil
,15993026,times,"The times for the unchanged modafinil to reach peak concentration in the urine of the three volunteers were at 2 h (6.14 microg/mL), 4 h (9.93 microg/mL) and 8 h (3.58 microg/mL), respectively.",Detection of modafinil in human urine by gas chromatography-mass spectrometry. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15993026/),h,8,38528,DB00745,Modafinil
,15993026,times,"The times for the unchanged modafinil to reach peak concentration in the urine of the three volunteers were at 2 h (6.14 microg/mL), 4 h (9.93 microg/mL) and 8 h (3.58 microg/mL), respectively.",Detection of modafinil in human urine by gas chromatography-mass spectrometry. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15993026/),[μg] / [ml],3.58,38529,DB00745,Modafinil
,15993026,to reach peak concentration,"The times for the unchanged modafinil to reach peak concentration in the urine of the three volunteers were at 2 h (6.14 microg/mL), 4 h (9.93 microg/mL) and 8 h (3.58 microg/mL), respectively.",Detection of modafinil in human urine by gas chromatography-mass spectrometry. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15993026/),h,2,38530,DB00745,Modafinil
,15993026,to reach peak concentration,"The times for the unchanged modafinil to reach peak concentration in the urine of the three volunteers were at 2 h (6.14 microg/mL), 4 h (9.93 microg/mL) and 8 h (3.58 microg/mL), respectively.",Detection of modafinil in human urine by gas chromatography-mass spectrometry. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15993026/),[μg] / [ml],6.14,38531,DB00745,Modafinil
,15993026,to reach peak concentration,"The times for the unchanged modafinil to reach peak concentration in the urine of the three volunteers were at 2 h (6.14 microg/mL), 4 h (9.93 microg/mL) and 8 h (3.58 microg/mL), respectively.",Detection of modafinil in human urine by gas chromatography-mass spectrometry. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15993026/),h,4,38532,DB00745,Modafinil
,15993026,to reach peak concentration,"The times for the unchanged modafinil to reach peak concentration in the urine of the three volunteers were at 2 h (6.14 microg/mL), 4 h (9.93 microg/mL) and 8 h (3.58 microg/mL), respectively.",Detection of modafinil in human urine by gas chromatography-mass spectrometry. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15993026/),[μg] / [ml],9.93,38533,DB00745,Modafinil
,15993026,to reach peak concentration,"The times for the unchanged modafinil to reach peak concentration in the urine of the three volunteers were at 2 h (6.14 microg/mL), 4 h (9.93 microg/mL) and 8 h (3.58 microg/mL), respectively.",Detection of modafinil in human urine by gas chromatography-mass spectrometry. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15993026/),h,8,38534,DB00745,Modafinil
,15993026,to reach peak concentration,"The times for the unchanged modafinil to reach peak concentration in the urine of the three volunteers were at 2 h (6.14 microg/mL), 4 h (9.93 microg/mL) and 8 h (3.58 microg/mL), respectively.",Detection of modafinil in human urine by gas chromatography-mass spectrometry. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15993026/),[μg] / [ml],3.58,38535,DB00745,Modafinil
,22039290,EC(50),"Armodafinil 200 mg produced a plasma concentration above the EC(50) (4.6 µg/mL) for 9 hours, whereas modafinil 200 mg did not exceed the EC(50).",Armodafinil and modafinil in patients with excessive sleepiness associated with shift work disorder: a pharmacokinetic/pharmacodynamic model for predicting and comparing their concentration-effect relationships. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22039290/),[μg] / [ml],4.6,67027,DB00745,Modafinil
,22039290,times,"Consequently, armodafinil produced greater increases in predicted placebo-subtracted MSLT times of 0.5-1 minute (up to 10 hours after dosing) compared with modafinil.",Armodafinil and modafinil in patients with excessive sleepiness associated with shift work disorder: a pharmacokinetic/pharmacodynamic model for predicting and comparing their concentration-effect relationships. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22039290/),min,0.5-1,67028,DB00745,Modafinil
,29178272,AUC ratios,"Following a single 200 mg dose of modafinil mean (± 95% CI) AUC ratios for caffeine, dextromethorphan, losartan, midazolam and omeprazole were 0.95 (± 0.08), 1.01 (± 0.35), 0.97 (± 0.10), 0.98 (± 0.10) and 1.36 (± 0.06), respectively.",Evaluation of modafinil as a perpetrator of metabolic drug-drug interactions using a model informed cocktail reaction phenotyping trial protocol. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29178272/),,0.95,81454,DB00745,Modafinil
,29178272,AUC ratios,"Following a single 200 mg dose of modafinil mean (± 95% CI) AUC ratios for caffeine, dextromethorphan, losartan, midazolam and omeprazole were 0.95 (± 0.08), 1.01 (± 0.35), 0.97 (± 0.10), 0.98 (± 0.10) and 1.36 (± 0.06), respectively.",Evaluation of modafinil as a perpetrator of metabolic drug-drug interactions using a model informed cocktail reaction phenotyping trial protocol. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29178272/),,1.01,81455,DB00745,Modafinil
,29178272,AUC ratios,"Following a single 200 mg dose of modafinil mean (± 95% CI) AUC ratios for caffeine, dextromethorphan, losartan, midazolam and omeprazole were 0.95 (± 0.08), 1.01 (± 0.35), 0.97 (± 0.10), 0.98 (± 0.10) and 1.36 (± 0.06), respectively.",Evaluation of modafinil as a perpetrator of metabolic drug-drug interactions using a model informed cocktail reaction phenotyping trial protocol. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29178272/),,0.97,81456,DB00745,Modafinil
,29178272,AUC ratios,"Following a single 200 mg dose of modafinil mean (± 95% CI) AUC ratios for caffeine, dextromethorphan, losartan, midazolam and omeprazole were 0.95 (± 0.08), 1.01 (± 0.35), 0.97 (± 0.10), 0.98 (± 0.10) and 1.36 (± 0.06), respectively.",Evaluation of modafinil as a perpetrator of metabolic drug-drug interactions using a model informed cocktail reaction phenotyping trial protocol. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29178272/),,0.98,81457,DB00745,Modafinil
,29178272,AUC ratios,"Following a single 200 mg dose of modafinil mean (± 95% CI) AUC ratios for caffeine, dextromethorphan, losartan, midazolam and omeprazole were 0.95 (± 0.08), 1.01 (± 0.35), 0.97 (± 0.10), 0.98 (± 0.10) and 1.36 (± 0.06), respectively.",Evaluation of modafinil as a perpetrator of metabolic drug-drug interactions using a model informed cocktail reaction phenotyping trial protocol. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29178272/),,1.36,81458,DB00745,Modafinil
,29178272,AUC ratios,"Following dosing of modafinil to steady state (200 mg for 7 days), AUC ratios for caffeine, dextromethorphan, losartan, midazolam and omeprazole were 0.90 (± 0.16), 0.79 (± 0.09), 0.98 (± 0.11), 0.66 (± 0.12) and 1.90 (± 0.53), respectively.",Evaluation of modafinil as a perpetrator of metabolic drug-drug interactions using a model informed cocktail reaction phenotyping trial protocol. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29178272/),,0.90,81459,DB00745,Modafinil
,29178272,AUC ratios,"Following dosing of modafinil to steady state (200 mg for 7 days), AUC ratios for caffeine, dextromethorphan, losartan, midazolam and omeprazole were 0.90 (± 0.16), 0.79 (± 0.09), 0.98 (± 0.11), 0.66 (± 0.12) and 1.90 (± 0.53), respectively.",Evaluation of modafinil as a perpetrator of metabolic drug-drug interactions using a model informed cocktail reaction phenotyping trial protocol. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29178272/),,0.79,81460,DB00745,Modafinil
,29178272,AUC ratios,"Following dosing of modafinil to steady state (200 mg for 7 days), AUC ratios for caffeine, dextromethorphan, losartan, midazolam and omeprazole were 0.90 (± 0.16), 0.79 (± 0.09), 0.98 (± 0.11), 0.66 (± 0.12) and 1.90 (± 0.53), respectively.",Evaluation of modafinil as a perpetrator of metabolic drug-drug interactions using a model informed cocktail reaction phenotyping trial protocol. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29178272/),,0.98,81461,DB00745,Modafinil
,29178272,AUC ratios,"Following dosing of modafinil to steady state (200 mg for 7 days), AUC ratios for caffeine, dextromethorphan, losartan, midazolam and omeprazole were 0.90 (± 0.16), 0.79 (± 0.09), 0.98 (± 0.11), 0.66 (± 0.12) and 1.90 (± 0.53), respectively.",Evaluation of modafinil as a perpetrator of metabolic drug-drug interactions using a model informed cocktail reaction phenotyping trial protocol. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29178272/),,0.66,81462,DB00745,Modafinil
,29178272,AUC ratios,"Following dosing of modafinil to steady state (200 mg for 7 days), AUC ratios for caffeine, dextromethorphan, losartan, midazolam and omeprazole were 0.90 (± 0.16), 0.79 (± 0.09), 0.98 (± 0.11), 0.66 (± 0.12) and 1.90 (± 0.53), respectively.",Evaluation of modafinil as a perpetrator of metabolic drug-drug interactions using a model informed cocktail reaction phenotyping trial protocol. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29178272/),,1.90,81463,DB00745,Modafinil
,17765221,K(i),"JNJ-28583867 (2-Methyl-4-(4-methylsulfanyl-phenyl)-7-(3-morpholin-4-yl-propoxy)-1,2,3,4-tetrahydro-isoquinoline) is a selective and potent histamine H(3) receptor antagonist (K(i)=10.6 nM) and inhibitor of the serotonin transporter (SERT) (K(i)=3.7 nM), with 30-fold selectivity for SERT over the dopamine and norepinephrine transporters.","Pharmacological characterization of JNJ-28583867, a histamine H(3) receptor antagonist and serotonin reuptake inhibitor. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17765221/),nM,10.6,87547,DB00745,Modafinil
,17765221,K(i),"JNJ-28583867 (2-Methyl-4-(4-methylsulfanyl-phenyl)-7-(3-morpholin-4-yl-propoxy)-1,2,3,4-tetrahydro-isoquinoline) is a selective and potent histamine H(3) receptor antagonist (K(i)=10.6 nM) and inhibitor of the serotonin transporter (SERT) (K(i)=3.7 nM), with 30-fold selectivity for SERT over the dopamine and norepinephrine transporters.","Pharmacological characterization of JNJ-28583867, a histamine H(3) receptor antagonist and serotonin reuptake inhibitor. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17765221/),nM,3.7,87548,DB00745,Modafinil
,17765221,oral bioavailability,"JNJ-28583867 has good oral bioavailability in the rat (32%), a half-life of 6.9 h and a C(max) of 260 ng/ml after 10 mg/kg p.o.","Pharmacological characterization of JNJ-28583867, a histamine H(3) receptor antagonist and serotonin reuptake inhibitor. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17765221/),%,32,87549,DB00745,Modafinil
,17765221,half-life,"JNJ-28583867 has good oral bioavailability in the rat (32%), a half-life of 6.9 h and a C(max) of 260 ng/ml after 10 mg/kg p.o.","Pharmacological characterization of JNJ-28583867, a histamine H(3) receptor antagonist and serotonin reuptake inhibitor. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17765221/),h,6.9,87550,DB00745,Modafinil
,17765221,C(max),"JNJ-28583867 has good oral bioavailability in the rat (32%), a half-life of 6.9 h and a C(max) of 260 ng/ml after 10 mg/kg p.o.","Pharmacological characterization of JNJ-28583867, a histamine H(3) receptor antagonist and serotonin reuptake inhibitor. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17765221/),[ng] / [ml],260,87551,DB00745,Modafinil
,20216121,clearance of central compartment,The estimated population parameters of modafinil were as follows: clearance of central compartment was 3.51 L/h and clearance of intercompartment was 7.41 L/h; the volume of the central compartment was 3.85 L and the volume of the peripheral compartment was 45.8 L.,"Population pharmacokinetics of modafinil in Chinese Han, Mongolian, Korean, Uygur, and Hui healthy subjects determined by nonlinear mixed-effects modeling. ",CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20216121/),[l] / [h],3.51,89710,DB00745,Modafinil
,20216121,clearance of intercompartment,The estimated population parameters of modafinil were as follows: clearance of central compartment was 3.51 L/h and clearance of intercompartment was 7.41 L/h; the volume of the central compartment was 3.85 L and the volume of the peripheral compartment was 45.8 L.,"Population pharmacokinetics of modafinil in Chinese Han, Mongolian, Korean, Uygur, and Hui healthy subjects determined by nonlinear mixed-effects modeling. ",CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20216121/),[l] / [h],7.41,89711,DB00745,Modafinil
,20216121,volume of the central compartment,The estimated population parameters of modafinil were as follows: clearance of central compartment was 3.51 L/h and clearance of intercompartment was 7.41 L/h; the volume of the central compartment was 3.85 L and the volume of the peripheral compartment was 45.8 L.,"Population pharmacokinetics of modafinil in Chinese Han, Mongolian, Korean, Uygur, and Hui healthy subjects determined by nonlinear mixed-effects modeling. ",V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20216121/),l,3.85,89712,DB00745,Modafinil
,20216121,volume of the peripheral compartment,The estimated population parameters of modafinil were as follows: clearance of central compartment was 3.51 L/h and clearance of intercompartment was 7.41 L/h; the volume of the central compartment was 3.85 L and the volume of the peripheral compartment was 45.8 L.,"Population pharmacokinetics of modafinil in Chinese Han, Mongolian, Korean, Uygur, and Hui healthy subjects determined by nonlinear mixed-effects modeling. ",V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20216121/),l,45.8,89713,DB00745,Modafinil
,12537513,elimination half-life,"The elimination half-life is approximately 12-15 hours, which is largely reflective of the pharmacokinetics of the longer-lived l-enantiomer.",Clinical pharmacokinetic profile of modafinil. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12537513/),h,12-15,99272,DB00745,Modafinil
,10073328,t1/2,Modafinil was rapidly absorbed after oral dosing and slowly cleared (t1/2 approximately 11-14 hr) from the body.,"Open-label, single-dose pharmacokinetic study of modafinil tablets: influence of age and gender in normal subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10073328/),h,11-14,124112,DB00745,Modafinil
,18536781,elimination half-life,"It is rapidly absorbed and eliminated, having a mean elimination half-life of 30-60 minutes.","Sodium oxybate: efficacy, safety and tolerability in the treatment of narcolepsy with or without cataplexy. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18536781/),min,30-60,124675,DB00745,Modafinil
,18613861,trough plasma concentration,"In study 2, the steady state was reached on day 4, and mean trough plasma concentration of modafinil was 1.36 +/- 0.34 mug/mL.",Pharmacokinetics and tolerability of modafinil tablets in Chinese subjects. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18613861/),[μg] / [ml],1.36,130934,DB00745,Modafinil
,19663523,terminal elimination half-life,"Armodafinil and modafinil both had a mean single-dose terminal elimination half-life of approximately 13 hours, with similar mean maximum plasma drug concentration (C(max)) and median time to C(max) values.","Armodafinil and modafinil have substantially different pharmacokinetic profiles despite having the same terminal half-lives: analysis of data from three randomized, single-dose, pharmacokinetic studies. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19663523/),h,13,135179,DB00745,Modafinil
,26387027,maximum plasma concentration (C max),Risperidone maximum plasma concentration (C max) decreased from mean 16.5 ng/mL when given alone to 9.2 ng/mL after armodafinil pretreatment (geometric mean ratio [90 % CI] 0.55 [0.50-0.61]); area under the plasma concentration-time curve from time 0 to infinity (AUC0-∞) decreased from 92.3 to 44.5 ng·h/mL (geometric mean ratio [90 % CI] 0.51 [0.46-0.55]).,Evaluation of potential pharmacokinetic drug-drug interaction between armodafinil and risperidone in healthy adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26387027/),[ng] / [ml],16.5,135343,DB00745,Modafinil
,26387027,maximum plasma concentration (C max),Risperidone maximum plasma concentration (C max) decreased from mean 16.5 ng/mL when given alone to 9.2 ng/mL after armodafinil pretreatment (geometric mean ratio [90 % CI] 0.55 [0.50-0.61]); area under the plasma concentration-time curve from time 0 to infinity (AUC0-∞) decreased from 92.3 to 44.5 ng·h/mL (geometric mean ratio [90 % CI] 0.51 [0.46-0.55]).,Evaluation of potential pharmacokinetic drug-drug interaction between armodafinil and risperidone in healthy adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26387027/),[ng] / [ml],9.2,135344,DB00745,Modafinil
,26387027,area under the plasma concentration-time curve from time 0 to infinity (AUC0-∞),Risperidone maximum plasma concentration (C max) decreased from mean 16.5 ng/mL when given alone to 9.2 ng/mL after armodafinil pretreatment (geometric mean ratio [90 % CI] 0.55 [0.50-0.61]); area under the plasma concentration-time curve from time 0 to infinity (AUC0-∞) decreased from 92.3 to 44.5 ng·h/mL (geometric mean ratio [90 % CI] 0.51 [0.46-0.55]).,Evaluation of potential pharmacokinetic drug-drug interaction between armodafinil and risperidone in healthy adults. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26387027/),[h·ng] / [ml],92.3,135345,DB00745,Modafinil
,26387027,area under the plasma concentration-time curve from time 0 to infinity (AUC0-∞),Risperidone maximum plasma concentration (C max) decreased from mean 16.5 ng/mL when given alone to 9.2 ng/mL after armodafinil pretreatment (geometric mean ratio [90 % CI] 0.55 [0.50-0.61]); area under the plasma concentration-time curve from time 0 to infinity (AUC0-∞) decreased from 92.3 to 44.5 ng·h/mL (geometric mean ratio [90 % CI] 0.51 [0.46-0.55]).,Evaluation of potential pharmacokinetic drug-drug interaction between armodafinil and risperidone in healthy adults. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26387027/),[h·ng] / [ml],44,135346,DB00745,Modafinil
,19133704,elimination half-life,"After reaching the peak, plasma concentrations of armodafinil declined in a monophasic manner, with a mean elimination half-life of approximately 15 hours.",Pharmacokinetic profile of armodafinil in healthy subjects: pooled analysis of data from three randomized studies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19133704/),h,15,144418,DB00745,Modafinil
,19133704,elimination half-life,"After reaching peak plasma levels, concentrations of armodafinil declined monophasically, with a mean elimination half-life of around 15 hours.",Pharmacokinetic profile of armodafinil in healthy subjects: pooled analysis of data from three randomized studies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19133704/),h,15,144419,DB00745,Modafinil
,22222607,linear dynamic,The assay exhibited a linear dynamic range of 1-2000 ng/mL for ambrisentan in plasma.,LC-ESI-MS/MS method for quantification of ambrisentan in plasma and application to rat pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22222607/),[ng] / [ml],1-2000,145656,DB00745,Modafinil
,22222607,maximum mean concentration in plasma (C(max),"Following oral administration the maximum mean concentration in plasma (C(max) ; 1197 ± 179 ng/mL) was achieved at 1.0 ± 0.9 h (T(max) ), and the area under the curve (AUC) was 6013 ± 997 ng h/mL.",LC-ESI-MS/MS method for quantification of ambrisentan in plasma and application to rat pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22222607/),[ng] / [ml],1197,145657,DB00745,Modafinil
,22222607,T(max),"Following oral administration the maximum mean concentration in plasma (C(max) ; 1197 ± 179 ng/mL) was achieved at 1.0 ± 0.9 h (T(max) ), and the area under the curve (AUC) was 6013 ± 997 ng h/mL.",LC-ESI-MS/MS method for quantification of ambrisentan in plasma and application to rat pharmacokinetic study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22222607/),h,1.0,145658,DB00745,Modafinil
,22222607,area under the curve (AUC),"Following oral administration the maximum mean concentration in plasma (C(max) ; 1197 ± 179 ng/mL) was achieved at 1.0 ± 0.9 h (T(max) ), and the area under the curve (AUC) was 6013 ± 997 ng h/mL.",LC-ESI-MS/MS method for quantification of ambrisentan in plasma and application to rat pharmacokinetic study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22222607/),[h·ng] / [ml],6013,145659,DB00745,Modafinil
,22105589,minimum trough plasma modafinil concentrations,The authors developed dosing schedules to achieve minimum trough plasma modafinil concentrations of 3 mcg/mL.,Population pharmacokinetics of modafinil and its acid and sulfone metabolites in Chinese males. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22105589/),[mcg] / [ml],3,146234,DB00745,Modafinil
,22493813,t1/2alpha,"The main pharmacokinetic parameters t1/2alpha, t1/2beta, t(max), C(max) and AUC(0-inifinity) were 0.42 h, 3.10 h, 1.00 h, 41.34 mg x L(-1) and 142.22 mg x L(-1) x h, respectively.",[Pharmacokinetics--pharmacodynamics of modafinil in mice]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22493813/),h,0.42,148241,DB00745,Modafinil
,22493813,AUC(0-inifinity),"The main pharmacokinetic parameters t1/2alpha, t1/2beta, t(max), C(max) and AUC(0-inifinity) were 0.42 h, 3.10 h, 1.00 h, 41.34 mg x L(-1) and 142.22 mg x L(-1) x h, respectively.",[Pharmacokinetics--pharmacodynamics of modafinil in mice]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22493813/),[h·mg] / [l],142.22,148242,DB00745,Modafinil
,12657914,limits of detection,The limits of detection (0.01 microg/mL) and quantitation (0.5 microg/mL) were well below the concentration expected in serum from patients receiving therapeutic doses of modafinil.,Chiral analysis of d- and l-modafinil in human serum: application to human pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12657914/),[μg] / [ml],0.01,159323,DB00745,Modafinil
,7911706,run time,The run time was 45 in.,Simultaneous determination of modafinil and its acid metabolite by high-performance liquid chromatography in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7911706/),in,45,174678,DB00745,Modafinil
,7911706,detection limit,"The method provided a detection limit of 0.04 mg/l for modafinil and the acid metabolite, a quantitation limit of 0.13 mg/l for modafinil and 0.14 mg/l for the acid metabolite.",Simultaneous determination of modafinil and its acid metabolite by high-performance liquid chromatography in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7911706/),[mg] / [l],0.04,174679,DB00745,Modafinil
,20607239,MTD,DLTs of reversible grade 3 benzodiazepine-like effects defined the estimated MTD of 60 mg QID/M for 14 days.,"Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20607239/),,60,212039,DB00745,Modafinil
,20607239,terminal half-life,"MLN8054 was absorbed rapidly, exposure was dose proportional, and terminal half-life was 30-40 h.","Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20607239/),h,30-40,212040,DB00745,Modafinil
,27436172,apparent oral clearance (CL/F),"Estimated armodafinil apparent oral clearance (CL/F), volume of distribution (Vc/F), and absorption t½ were 2.01 L/h, 45 L, and 0.226 hours, respectively.",Population Pharmacokinetic Modeling of Armodafinil and Its Major Metabolites. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27436172/),[l] / [h],2.01,240084,DB00745,Modafinil
,27436172,volume of distribution (Vc/F),"Estimated armodafinil apparent oral clearance (CL/F), volume of distribution (Vc/F), and absorption t½ were 2.01 L/h, 45 L, and 0.226 hours, respectively.",Population Pharmacokinetic Modeling of Armodafinil and Its Major Metabolites. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27436172/),l,45,240085,DB00745,Modafinil
,27436172,absorption t½,"Estimated armodafinil apparent oral clearance (CL/F), volume of distribution (Vc/F), and absorption t½ were 2.01 L/h, 45 L, and 0.226 hours, respectively.",Population Pharmacokinetic Modeling of Armodafinil and Its Major Metabolites. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27436172/),h,0.226,240086,DB00745,Modafinil
,27436172,CL/F,"CL/F and Vc/F for R-modafinil acid and modafinil sulfone were 16.7 L/h and 8.95 L and 6.82 L/h and 12.4 L, respectively.",Population Pharmacokinetic Modeling of Armodafinil and Its Major Metabolites. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27436172/),[l] / [h],16.7,240087,DB00745,Modafinil
,27436172,CL/F,"CL/F and Vc/F for R-modafinil acid and modafinil sulfone were 16.7 L/h and 8.95 L and 6.82 L/h and 12.4 L, respectively.",Population Pharmacokinetic Modeling of Armodafinil and Its Major Metabolites. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27436172/),[l] / [h],6.82,240088,DB00745,Modafinil
,27436172,Vc/F,"CL/F and Vc/F for R-modafinil acid and modafinil sulfone were 16.7 L/h and 8.95 L and 6.82 L/h and 12.4 L, respectively.",Population Pharmacokinetic Modeling of Armodafinil and Its Major Metabolites. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27436172/),l,8.95,240089,DB00745,Modafinil
,27436172,Vc/F,"CL/F and Vc/F for R-modafinil acid and modafinil sulfone were 16.7 L/h and 8.95 L and 6.82 L/h and 12.4 L, respectively.",Population Pharmacokinetic Modeling of Armodafinil and Its Major Metabolites. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27436172/),l,12.4,240090,DB00745,Modafinil
,19353685,flow rate,The separation was accomplished on a normal-phase polysaccharide stationary phase Chiralcel OJ-H using n-hexane-ethanol (62:38 v/v) as a mobile phase at a flow rate of 1.0 mL/min.,Enantioselective separation and determination of adrafinil and modafinil on Chiralcel OJ-H column in rat serum and urine using solid-phase extraction followed by HPLC. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19353685/),[ml] / [min],1.0,243377,DB00745,Modafinil
>or=,19353685,recoveries,ADL and its metabolite were recovered from rat serum and urine by solid phase extraction using Oasis HLB cartridges and the mean recoveries were >or=80%.,Enantioselective separation and determination of adrafinil and modafinil on Chiralcel OJ-H column in rat serum and urine using solid-phase extraction followed by HPLC. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19353685/),%,80,243378,DB00745,Modafinil
,9987698,plasma clearance,"Steady-state pharmacokinetics of modafinil were characterized by a rapid oral absorption rate, a low plasma clearance of approximately 50 mL/min, a volume of distribution of approximately 0.8 L/kg, and a long half-life of approximately 15 hr.","A double-blind, placebo-controlled, ascending-dose evaluation of the pharmacokinetics and tolerability of modafinil tablets in healthy male volunteers. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9987698/),[ml] / [min],50,246430,DB00745,Modafinil
,9987698,volume of distribution,"Steady-state pharmacokinetics of modafinil were characterized by a rapid oral absorption rate, a low plasma clearance of approximately 50 mL/min, a volume of distribution of approximately 0.8 L/kg, and a long half-life of approximately 15 hr.","A double-blind, placebo-controlled, ascending-dose evaluation of the pharmacokinetics and tolerability of modafinil tablets in healthy male volunteers. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9987698/),[l] / [kg],0.8,246431,DB00745,Modafinil
,9987698,half-life,"Steady-state pharmacokinetics of modafinil were characterized by a rapid oral absorption rate, a low plasma clearance of approximately 50 mL/min, a volume of distribution of approximately 0.8 L/kg, and a long half-life of approximately 15 hr.","A double-blind, placebo-controlled, ascending-dose evaluation of the pharmacokinetics and tolerability of modafinil tablets in healthy male volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9987698/),h,15,246432,DB00745,Modafinil
,23103618,clearance,"The typical clearance and volume of distribution for modafinil acid were 4.94 (l/h) and 2.73 (l), respectively.",Population pharmacokinetics of modafinil acid and estimation of the metabolic conversion of modafinil into modafinil acid in 5 major ethnic groups of China. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23103618/),[l] / [h],4.94,273755,DB00745,Modafinil
,23103618,volume of distribution,"The typical clearance and volume of distribution for modafinil acid were 4.94 (l/h) and 2.73 (l), respectively.",Population pharmacokinetics of modafinil acid and estimation of the metabolic conversion of modafinil into modafinil acid in 5 major ethnic groups of China. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23103618/),l,2.73,273756,DB00745,Modafinil
,23103618,relative conversion fraction,"The median for the relative conversion fraction was 0.53 for Koreans, and 0.24 for the other 4 ethnicities.",Population pharmacokinetics of modafinil acid and estimation of the metabolic conversion of modafinil into modafinil acid in 5 major ethnic groups of China. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23103618/),,0.53,273757,DB00745,Modafinil
,23103618,relative conversion fraction,"The median for the relative conversion fraction was 0.53 for Koreans, and 0.24 for the other 4 ethnicities.",Population pharmacokinetics of modafinil acid and estimation of the metabolic conversion of modafinil into modafinil acid in 5 major ethnic groups of China. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23103618/),,0.24,273758,DB00745,Modafinil
